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Colorectal cancer (CRC) 
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Abstract 
 
Background and Aims  
The optimal timing of treatment escalation in Crohn’s disease (CD) remains a challenge and 
very little is known about its long-term development following early versus late 
administration of anti-TNF antibodies. The long-term outcome of Swiss CD patients was 
comparatively assessed in an up to 10-year follow-up, using patients participating in the 
Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). 
 
Methods 
Prospectively-collected SIBDCS patient data, including disease history, baseline 
characteristics at enrolment and course of disease were analysed in patients with early 
versus late (<24 versus >=24 months after diagnosis) and no anti-TNF treatment. 
 
Results 
A reduced risk of developing bowel stenosis was found in patients who received early anti-
TNF treatment. This association was seen in patients overall and also in the subgroups of CD 
patients without pre-existing complications (Log-rank test: p<0.001).  
Furthermore, osteoporosis and anaemia were observed significantly less frequently in 
patients who received early anti-TNF treatment, compared to either patients who received 
treatment late (p<0.001 and p=0.046, respectively) or were never (p<0.001 for both) treated 
with anti-TNF antibodies. Patients with early anti-TNF administration sought medical 
consultations significantly less often, including gastroenterologists in private practice 
(p=0.017), ambulatory (outpatient) hospital visits (p=0.038) and a composite of any medical 
visits (p=0.001). The percentage of patients unable to work was lowest for early anti-TNF 
treated patients, in comparison to patients who were treated late or never (3.6% versus 8.8% 
versus 3.7%, p=0.016). 
 
Conclusions 
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Early anti-TNF administration was found to be associated with several indicators of a more 
favourable long-term outcome, in CD patients within the SIBDCS. 
 
 
Key words 
anti-TNF, early intervention, long-term outcome 
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Introduction 
 
The optimal management of patients suffering from chronic inflammatory illnesses such as 
Crohn’s disease (CD), has not been clarified and remains a matter for ongoing research. A major 
challenge lies in predicting the future course of the disease, which is difficult or even impossible, 
with the tools currently available in clinical practice [1].  
However, the approval of anti-tumour necrosis factor (TNF) drugs in 1998 was an important 
breakthrough in CD therapy [2]. 
The substantial value of anti-TNF drugs was soon realized, and new possibilities for disease 
control seemed achievable. The TNF inhibitors’ strong, anti-inflammatory activity made it 
possible to use a ‘treat to target’ approach for treating patients, aimed at going beyond mere 
symptom surveillance and clinical remission, to complete control of inflammation [3]. 
Individualised therapies might be state of the art even in the nearer future. A potentially 
beneficial impact of anti-TNF drugs on the progress of the disease’s course, was indicated in 
both animal [4] and cohort studies in humans [5-7]. 
In addition, several studies have compared ‘step-up’ and ‘top-down’ treatment strategies in CD 
[8-10]. The current literature favours a ‘rapid step-up’ strategy, with early, stepwise 
introduction of immunosuppressive agents (IM) and the timely addition of anti-TNF [11-14], 
although the benefit of early IM remains controversial [13, 15]. The impact of a ‘top-down’ 
strategy, with early introduction of anti-TNF, including the key question, whether the disease’s 
course can be modified through early anti-TNF administration has been investigated by even 
more studies [4, 16-24].  
However, the evidence for a potentially beneficial impact on the disease’s course and knowledge 
about the proper selection of patients in need of an early, aggressive treatment, remains limited. 
In particular, the disease’s long-term development beyond the usual observation periods of one 
year, in most studies, or 5 years in very few instances, remains unknown. 
Using the prospectively obtained data from patients participating in the SIBDCS, the study aimed 
to investigate whether early anti-TNF administration, defined as initiation during the first 24 
months after CD diagnosis, is associated with beneficial effects on predefined outcome 
parameters in CD, compared to patients with anti-TNF initiation later than the first 24 months 
since diagnosis or patients without anti-TNF treatment. 
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz057/5373083 by U
niversitaetsbibliothek Bern user on 18 M
arch 2019
Ac
ce
pt
ed
 M
an
us
cr
ipt
Manuscript Doi: 10.1093/ecco-jcc/jjz057 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz057/5373083 by U
niversitaetsbibliothek Bern user on 18 M
arch 2019
Ac
ce
pt
ed
 M
an
us
cr
ipt
Manuscript Doi: 10.1093/ecco-jcc/jjz057 
 
 
Materials and Methods 
 
Study Population: 
The nationwide inclusion of IBD patients into the SIBDCS began in 2006. The SIBDCS was 
designed as a prospective cohort study. All the patients provided written, informed consent for 
participation in the study at enrolment. SIBDCS receives ongoing supporting grants from the 
Swiss National Science Foundation (SNSF) and has been approved by all participating centres’ 
local ethical committees. SIBDCS has been described in detail by Pittet et al. [25, 26]. 
At the time of inclusion into the study, the patients and the treating physicians completed 
enrolment questionnaires. The patient questionnaires contained questions about the individual 
perception of the clinical course of the disease, the severity of symptoms, as well as quality of life 
(QoL), and socioeconomic associations. The physician questionnaires focused on clinical 
characteristics, the classification and course of IBD. Both patients and treating physicians are 
followed up annually by follow-up questionnaires similar to the original inclusion 
questionnaires. 
Data from all the CD patients enrolled into SIBDCS since its start in 2006, have been used for the 
analysis in this study. Data extraction, from the SIBDCS data base, as well as the subsequent 
statistical analysis, were performed at the SIBDCS data centre in Lausanne, Switzerland.  
 
Data extractions, definitions:  
All the data for this study were collected prospectively through the SIBDCS cohort study and 
analysed retrospectively at the cut-off date: 12/31/2016 for our study. Anti-TNF medication was 
defined as the administration of at least one dose of the three anti-TNF agents currently 
approved for the treatment of CD in Switzerland, i.e. infliximab, adalimumab or certolizumab 
pegol, during the observation period. 
Three groups were defined in order to assess the impact of the timing of anti-TNF 
administration on the course of the disease: ‘early anti-TNF’, i.e. patients who received anti-TNF 
within the first 24 months following diagnosis;  ‘late anti-TNF’, i.e. patients who received anti-
TNF medication more than 24 months after diagnosis and ‘no anti-TNF’, i.e. patients who 
received no anti-TNF therapy following IBD diagnosis during the observation period. 
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The study’s primary outcomes included bowel stenosis, perianal fistula, other fistula, any fistula, 
perianal surgery, intestinal surgery, any surgery and extraintestinal manifestations (EIM). These 
outcome parameters were analysed using the log-rank test, looking at the time to the first 
complication. Secondary outcomes included the occurrence of osteoporosis and anaemia, 
utilization of health care resources and inability to work because of CD (absence from work due 
to other reasons was not included in these analyses). The rates of occurrence of secondary 
outcomes between different treatment groups were compared.  
Safety data included rates and differences in occurrence of colorectal cancer (CRC) and intestinal 
lymphomas (IL). In addition, the rates of opportunistic infections leading to the cessation of anti-
TNF therapy, were also assessed. 
In the survival analysis for the primary outcomes, patients who were treated early (<24 
months), were compared with patients who were treated with anti-TNF agents later (>=24 
months). Pre-existing complications, which were analysed as primary outcomes during follow-
up after anti-TNF induction, were defined as any single occurrence or a continuance of the same 
complications which already existed prior to anti-TNF induction. 
There is a lack of standardized definitions for bowel stenosis, which a very recent expert 
consensus has aimed to overcome. According to this consensus, the best current definition of 
small bowel stricture is based on a combination of wall thickening, luminal narrowing and pre-
stenotic dilation [27]. In conjunction with these parameters, the assessment of clinical 
symptoms and signs, radiological examinations and endoscopy were used to diagnose bowel 
stenosis in this study. 
‘Perianal fistula’ refers to any kind of fistula located in the perianal area, such as submucosal, 
intersphincteric, transsphincteric, suprasphincteric or extrasphincteric fistulas. ‘Other fistula’ 
refers to any kind of non-perianal fistula, whereas ‘any fistula’ combines perianal and all kinds of 
non-perianal fistula. Likewise, ‘perianal surgery’ refers to perianal surgical procedures, such as 
drainage of perianal abscesses, seton-placement or any form of fistula extraction/closure 
procedure, whereas ‘intestinal surgery’ refers to any kind of CD-related surgery performed on 
the intestine, including any kind of resection or ostomy surgery. Again, ‘any surgery’ refers to 
the need for any CD-related surgery, irrespective of the location or type of procedure.  
EIM includes peripheral arthritis/arthralgia, uveitis/iritis, pyoderma gangrenosum, erythema 
nodosum, aphthous oral ulcers/stomatitis, ankylosing spondylitis (Bechterew), sacroiliitis and 
primary sclerosing cholangitis.  
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Regarding secondary outcomes osteoporosis and anaemia were assessed due to their clinical 
relevance.  
Furthermore, the study tested for differences in the utilization of health care resources across 
treatment groups. Therefore, CD-related medical visits to general practitioners, 
gastroenterologists in private practice, ambulatory visits to hospitals and hospitalisations were 
assessed. The category ‘other’ includes medical visits to any physician not included in the 
predefined categories above, for example specialised surgeons such as coloproctologists. The 
data on utilization of health care resources was collected in every patient questionnaire and 
took the last three months of each annual follow-up questionnaire into account. The three 
months recall period was chosen in cooperation with experts in public health and psychologists, 
which have been involved in the SIBDCS from the very beginning until now. The three-month-
interval was considered optimal for minimizing the risk of recall bias and inadequate data. 
Like data on utilization of health care resources, data on ability to work was also assessed with 
every annual patient questionnaire for the last three months antecedent to the follow-up. 
 
Statistical Analysis 
All statistical analyses were carried out using the Stata Software (v. 14.2, StataCorp, College 
Station, TX, USA). 
Categorical data were summarized as raw frequencies and relative percentages. Differences in 
categorical data distribution between two or more independent groups were assessed using the 
chi-squared test, or the Fisher’s exact test in case of low sample size. 
Continuous data distribution was assessed using normal, quantile-quantile (QQ)-plots. Gaussian 
distributed data were summarized as mean, standard deviation (SD) and range, while non-
Gaussian distributed data were summarized as median, interquartile range (IQR) and range. 
Differences in means for Gaussian distributed data between two independent groups were 
assessed using the Student’s t-test, or ANOVA, for more than two independent groups. 
Differences in distribution of non-Gaussian distributed data between two independent groups, 
were assessed using the Wilcoxon-Mann-Whitney rank-sum test, or the Kruskall-Wallis test for 
more than two groups. 
The primary outcomes were analysed as time-to-event data. The complication-free proportions 
according to time, were derived using Kaplan-Meyer survival estimator. The log-rank test was 
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used to assess overall differences between survival curves for independent groups. A p-value <= 
0.05 was considered to be statistically significant.  
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Results 
 
Study population 
During the ten-year period, from the start of patients’ inclusion into SIBDCS in early 2006 until 
the 31st of December 2016, a total of 1707 adult CD patients were enrolled, and 1592 patients’ 
data could be analysed (Figure 1). The study population’s demographic data and clinical 
characteristics are shown in Table 1. 
It is notable that patients who had received early anti-TNF therapy were younger (median age 
32 years vs. 44 years and 48 years, in late and no anti-TNF, respectively, p< 0.001) and had a 
shorter disease duration at the time of inclusion into the study, with a higher fraction of B1p 
phenotype.  
In terms of complications, those patients with no given pre-existing complication prior to anti-
TNF induction, were younger and had a shorter disease duration and lower rate of other 
complications, compared to their counterparts who had a respective pre-existing complication. 
However, for perianal surgery, there was no significant difference in age between patients with, 
compared to those without, perianal surgery prior to anti-TNF induction (p=0.067). There were 
also no significant differences in the presence of complications, other than EIM, between 
patients with or without EIM prior to anti-TNF induction (p=0.084). 
 
Disease course and complications 
 
Bowel stenosis 
A reduced risk of developing stenosis was found in early anti-TNF treated patients, compared to 
late anti-TNF treated patients, by using Kaplan-Meier analysis, as shown in Figure 2 (log-rank 
test: p<0.001). This difference was most pronounced in the subgroups of CD patients without 
pre-existing complication (log-rank test: p<0.001), whilst only by trend in patients with pre-
existing complication (p=0.147, Table 2). A significant difference between early and late anti-
TNF treated patients, was also detected when pre-existing complications were not considered 
(p<0.001, Supplementary Table 1). 
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Amongst those patients without bowel stenosis as a pre-existing complication, a larger number 
of early anti-TNF treated patients were free from the complication 2, 5 and 10 years after anti-
TNF initiation (95.1%, 83.6% and 67.8%, respectively), than late anti-TNF treated patients 
(88.1%, 68.2% and 45.7%, Supplementary Table 2). 
 
Penetrating complications and surgery 
Although a global difference was observed in the need for perianal surgery across the patient 
groups overall (p=0.002, Table 2), this difference was predominantly seen between patients 
with, compared to those without, pre-existing complications and was not dependent to early 
versus late anti-TNF treatment (Supplementary Figure 1).  
In addition, there were no significant differences favouring early intervention in terms of either 
intestinal or perianal surgery, nor for the occurrence of perianal fistula or fistula overall (Table 
2). 
Amongst those patients without any pre-existing penetrating complication or surgery, a larger 
number of early anti-TNF treated patients were still free from penetrating complications and 
surgeries 10 years after anti-TNF initiation (60.1%, 68.2%, 70.8% and 83.4%, respectively), 
compared to late anti-TNF treated patients (50.7%, 63.6%, 57.2% and 75.6%, Supplementary 
Table 2). 
 
Extraintestinal manifestations 
No difference was observed in the development of EIM, between early versus late anti-TNF 
treated patients without pre-existing complications (Supplementary Figure 2). However, early 
treated patients with pre-existing complications appeared to develop less EIM by trend 
(p=0.087, Table 2). 
When considering EIM as a pre-existing complication, a larger number of early anti-TNF treated 
patients were still free from EIM 2, 5 and 10 years after anti-TNF initiation (75.0%, 49.8% and 
26.3%, respectively), compared to late anti-TNF treated patients (74.7%, 46.8% and 22.1%, 
Supplementary Table 2). 
 
Osteoporosis and anaemia 
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Osteoporosis and anaemia were observed significantly less frequently in early versus late anti-
TNF treated patients (p<0.001 and p=0.046, respectively, Supplementary Table 3, Figure 3).  
 
Medical consultations and hospitalisations 
Patients who were administered anti-TNF early, needed medical consultations less often, 
including consultations with a gastroenterologist in private practice (p=0.017), ambulatory 
hospital visits (p=0.038) or a composite of any medical visits at all (p=0.001). There was, 
however, no difference in visits to a general practitioner or any other CD-related medical visits.  
Overall hospitalisations differed between the three groups tested, with the lowest number of 
hospitalisations in the group of patients who had never been treated with anti-TNF (p=0.001, 
Supplementary Table 4). However, there was no difference in hospitalisation rates between 
patients with early versus late, anti-TNF administration (Figure 4).  
 
Absence from work 
TNF treatment influenced work disability due to CD across all treatment groups (p=0.016, 
Supplementary Table 5). Early-treated patients were by trend, less likely to be unable to work, 
with 3.6% of patients being absent from work, compared to 8.8% of late-treated patients 
(p=0.096, Supplementary Table 5, Figure 5). 
 
Safety 
There were no significant differences in CRC or IL between the three different treatment groups 
(Supplementary Table 6). The absolute number of patients observed for whom opportunistic 
infection led to therapy cessation, was very low, with 1 patient (0.4%) from the early and 4 
patients (0.6%) from the late treatment group (Supplementary Figure 3). 
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Discussion 
In this study, an association was demonstrated between early anti-TNF administration and a 
reduced risk of developing bowel stenosis. In addition, patients with any pre-existing 
complication were relatively protected from a recurrence of this outcome 5 and 10 years after 
early versus late anti-TNF initiation, respectively. 
In particular, osteoporosis and anaemia were observed less frequently in the group of patients 
who received early anti-TNF treatment. Furthermore, patients with early anti-TNF 
administration sought medical consultations less frequently and by trend, showed lower rates of 
absence from work due to CD, compared to patients with late anti-TNF administration. 
In terms of stricturing disease behaviour, the study’s findings are in line with a previous SIBDCS 
study, in which a significant association between IM or anti-TNF agents and reduced bowel 
stenosis, was observed [16].  
As well as having a preventive effect, anti-TNF agents might also be effective in patients with 
established fibrotic disease. This has previously been suggested in a study by Allocca et al. [28] 
on stricturing CD, which showed that anti-TNF agents might prevent surgery in up to two-thirds 
of patients with intestinal stenosis. The beneficial effects of early anti-TNF administration seem 
to be selective for bowel stenosis, as neither the current study nor the previous investigations 
identified any effects on the overall need for surgery in CD [29-31].  
The reason why, in this study, stricturing disease appears to be more prone to modulation by 
early anti-TNF administration, as compared to penetrating disease, remains both unclear and 
also controversial. Some of the other recently published studies on this topic even indicated the 
opposite, showing that anti-TNF therapy might prevent the development of penetrating (B3) but 
not stricturing (B2), disease migration [32-34].  
A possible explanation for the present study’s findings might be that bowel stenosis and scar 
tissue formation result from the long-term, cumulative effects of continuous inflammation. 
Stopping or attenuating of inflammation at an early stage, might therefore prevent the ongoing 
progression of scar tissue formation, wall thickening, luminal narrowing and thus the 
development of stenosis over time [35-37]. In contrast, penetrating disease might manifest more 
suddenly at any time in the course of the disease [38], turning it out to be less susceptible to 
modification by early anti-TNF treatment. 
According to this study’s results, the overall need for surgery doesn’t appear to be affected by 
the timing of the anti-TNF intervention. This is in line with previous studies [39], which indicate 
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that the early use of anti-TNF can positively affect symptoms of stenosis but even though risk 
factors can be identified [40], might not yet be an appropriate strategy for reducing surgical 
interventions [30, 31, 41, 42]. 
In contrast to this, a retrospective analysis of Korean CD patients found significantly longer 
times to intestinal surgery (p< 0.001), stricturing complications (p= 0.002), and penetrating 
complications (p< 0.001) in the early anti-TNF/ IM groups, compared to the late treatment 
group [43]. 
The development of EIM does not seem to be affected by the timing of anti-TNF administration. 
In addition, pre-existing EIM does not seem to be affected differently by early or late, anti-TNF 
intervention. 
There are, however, studies about EIM and IBD phenotypes and medication, also including 
studies within the SIBDCS, which indicate that the presence of EIM is often associated with 
active disease, positive family history or treatment strategy (higher AZA exposure) [44, 45]. 
Nonetheless, to the best of the authors’ knowledge, there are no studies which address the best 
point in time for the administration of anti-TNF, regarding the development of EIM.  
In the present study, early anti-TNF administration was associated with a lower risk of 
osteoporosis, which remains a frequent problem in IBD patients [46]. In the past, infliximab 
therapy has been associated with increased biochemical markers for bone formation without 
increasing bone resorption [47]. Whether this might be due to a direct beneficial effect of TNF 
blockade on bone turnover, a beneficial effect on CD activity, resulting in decreased 
glucocorticoid exposure, or both, remains difficult to determine, especially as osteoporosis was 
not a primary outcome of this study.  
Early anti-TNF administration was found to be associated with a lower risk of anaemia. Short-
term anti-TNF therapy might significantly improve iron metabolism and, subsequently, anaemia 
in IBD [48]. This effect appears to be primarily related to the modulation of the cytokine 
network, leading to a relevant decrease of hepcidin, a master regulator of anaemia in chronic 
disease. On the other hand, during long-term treatment, anti-TNF therapy might also improve 
iron deficiency anaemia by inducing mucosal healing.  
The study identified a lower need for consultations with gastroenterologists in private practice 
and hospital outpatient visits in the early treatment group, but not for hospitalisation rates and 
general practitioner consultations. In a systemic review [49] which assessed the reduction in 
hospitalisation rates, as well as surgery rates, through immunosuppressive therapy, anti-TNF 
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agents reduced the probability of hospitalisation by half. The results of another investigation, 
revealing an association between timely anti-TNF administration and decrease in hospitalisation 
rates, are even more encouraging [50].  
There are only few studies investigating absence from work due to CD in relation to medical 
therapy [51-56], and to the best of the authors’ knowledge, no study has so far addressed the 
effects of anti-TNF treatment timing on CD-related work disability. This study showed 
significantly lower rates of absence from work for early anti-TNF treated CD patients, compared 
to late treated patients and an even slightly lower rate of work disability, compared to patients 
who have never been treated with anti-TNF. 
With the increasing availability of newer agents for treating IBD, the questions of positioning 
and determining the best timepoint during the course of the individual patient’s disease is 
becoming more immediate. Moving beyond anti-TNF, a multicentre, open-label phase IV trial 
(LOVE-CD; NCT02646683), is currently recruiting patients with CD; it aims to investigate 
whether there is a difference in clinical and endoscopic remission at week 26 (1°EP) between 
patients receiving early (<24months after diagnosis) versus late primary administration of 
vedolizumab. Similar studies which also consider complication rates, are desirable for other, 
newer agents, including ustekinumab and JAK-inhibitors. 
Our study has several strengths and limitations. One limitation is that, CD patients from tertiary 
care hospitals are over-represented within SIBDCS and the SIBDCS patient population cannot be 
considered to be fully population-based, as there is presumably a preponderance of patients 
with more severe disease. Moreover, data collected using questionnaires may be linked to a risk 
of bias, above all reporting and recall biases. Furthermore, no detailed data are available on the 
anti-TNF administration, in terms of individual doses and time intervals. The patient numbers in 
some of the subgroups analysed are rather small. This particularly applies to patients with early 
anti-TNF intervention and pre-existing complication of the respective outcome parameter. 
Nevertheless, those patient groups were kept in the analysis as the authors believe that they 
provide interesting information. Overall, it must be emphasized that the current investigation 
may not be sufficiently powered for any robust conclusions to be drawn with regards to the risk 
benefit balance for early anti-TNF administration. In terms of risks, severe adverse events (e.g. 
major infections requiring ICU or melanoma) have a tremendous impact but are fortunately 
infrequent. Due to the latter, a larger study population or large (multinational) patient registries 
would be advantageous. In addition, all the study’s findings represent associations and the 
underlying causes and effects remain the subject of speculation. Prospective, randomized long-
term studies would be needed to provide definite answers. However, such trials are virtually 
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impossible to perform. Therefore, prospective cohort studies are an adequate means of 
addressing the potential impact of early anti-TNF administration on the course of disease. The 
rigorous, annual follow-up, with detailed physician and patient questionnaires, is one of the 
study’s strengths. In addition, the long prospective follow-up period of up to 10 years, is another 
important strength.  
Furthermore, the present study may even have underestimated the benefit of early anti-TNF 
administration, since patients in the no anti-TNF group might have been positively selected 
because of having a less severe disease course (as indicated by several outcome parameters with 
apparently beneficial results for this group, including Crohn’s Disease Activity Index (CDAI) 
score, rates of hospitalisation, perianal fistula formation and perianal surgery). In view of this, 
the reduction in bowel stenosis, lower rates of osteoporosis and anaemia, fewer absences from 
work due to CD and fewer ambulatory hospital visits in the early treatment group shown by our 
study, indicate a truly beneficial effect.  
Importantly, one of the biggest risk factors for the development of any complication, appeared to 
be a prior history of exactly that complication. Regarding this factor, patients with or without a 
history of the respective complication were considered separately in the survival analysis, to 
distinguish the different preconditions in time to event.  
In conclusion, an association was observed between early anti-TNF administration and several 
beneficial clinical outcomes in CD, including reduced risks of bowel stenosis, osteoporosis and 
anaemia. In addition, lower rates of medical consultations and absences from work due to CD, 
were observed following early anti-TNF treatment. Accordingly, patients with a stricturing type 
(B2) or at risk of developing such a phenotype (i.e. those with long-segment or multi-segmental 
small bowel inflammatory lesions), might benefit most from an early anti-TNF intervention. The 
results therefore highlight the importance of properly identifying patients in need of early anti-
TNF administration, which currently remains a big challenge for the practicing clinicians, in the 
absence of high-accuracy tools for predicting the future course of CD. 
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Figures and Tables 
 
Figures 
Figure 1: Flowchart Study Population 
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Figure 2: Kaplan–Meier curves showing freedom from developing new bowel stenosis in 
patients treated early with anti- TNF agents compared to patients treated late with anti- TNF 
agents, with or without history of previous bowel stenosis 
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Figure 3: Frequency of osteoporosis and anaemia among the different treatment groups. CI: 
confidence interval 
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Figure 4: Frequency of patients with medical visits and hospitalisations related to IBD among 
the different treatment groups 
CI: confidence interval 
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Figure 5: Percentages of patients with absence from work among the three different treatment 
groups 
CI: confidence interval 
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Tables  
 
Anti-TNF 
treatment: 
Early 
treated 
(< 
24months) 
Late treated 
(>= 
24months) 
Never 
treated 
P-
value 
global 
P-value 
early vs. 
late 
Number of 
patients 
246 696 650   
Gender 
  Male 
  Female 
 
124 (50.4) 
122 (49.6) 
 
323 (46.4) 
373 (53.6) 
 
309 (47.5) 
341 (52.5) 
 
 
0.558 
 
 
0.280 
Age at diagnosis 
(years) 
(median, IQR, 
range) 
27, 20-38 
13-78 
24, 19-32 
3-75 
29, 22-41 
1-81 
 
<0.001 
 
<0.001 
Age (years) 
(median, IQR, 
range) 
32, 26-42 
17-88 
44, 34-53 
19-85 
48, 36-62 
18-89 
 
<0.001 
 
<0.001 
Disease duration 
(years) 
(median, IQR, 
range) 
5, 3-7 
0-16 
16, 11-23 
3-47 
13, 6-23 
0-57 
 
<0.001 
 
<0.001 
Months since  
last reported flare 
(median, IQR, 
range) 
 
12, 4-30 
0-60 
 
20, 8-36 
0-74 
 
16, 6-38 
0-77 
 
 
0.041 
 
 
0.011 
CDAI score at  
Last Follow-up 
(median, IQR, 
range) 
 
25, 6-54 
0-280 
 
26, 6-60 
0-339 
 
20, 6-46 
0-345 
 
 
0.001 
 
 
0.247 
Behaviour 
  B1 
  B1p 
  B2 
  B2p 
  B3 
  B3p 
 
94 (38.2) 
64 (26.0) 
42 (17.1) 
9 (3.7) 
17 (6.9) 
20 (8.1) 
 
185 (26.6) 
96 (13.8) 
152 (21.8) 
121 (17.4) 
46 (6.6) 
96 (13.8) 
 
325 (50.0) 
69 (10.6) 
123 (18.9) 
64 (9.9) 
42 (6.5) 
27 (4.2) 
 
 
 
 
 
 
<0.001 
 
 
 
 
 
 
<0.001 
Smoking status at 
diagnosis 
  Non-Smoker 
  Smoker 
  Unknown 
 
 
134 (54.5) 
102 (41.5) 
10 (4.0) 
 
 
325 (46.7) 
337 (48.4) 
34 (4.9) 
 
 
325 (50.0) 
302 (45.5) 
23 (4.5) 
 
 
 
 
0.222 
 
 
 
 
0.111 
Smoking status at 
latest follow-up 
  Non-Smoker 
  Smoker 
  Unknown 
 
 
163 (66.3) 
81 (32.9) 
2 (0.8) 
 
 
455 (65.4) 
238 (34.2) 
3 (0.4) 
 
 
462 (71.1) 
181 (27.9) 
7 (1.1) 
 
 
 
 
0.071 
 
 
 
 
0.694 
BMI 
(median, IQR, 
23.0, 20.2-
25.6 
22.9, 20.5-26.0 
14.7-45.4 
23.1, 20.7-
26.0 
 
0.307 
 
0.794 
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range) 14.6-50.1 13.9-48.1 
Table 1: Baseline characteristics and demographic data of study population.  
IQR: interquartile range 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz057/5373083 by U
niversitaetsbibliothek Bern user on 18 M
arch 2019
Ac
ce
pt
ed
 M
an
us
cr
ipt
Manuscript Doi: 10.1093/ecco-jcc/jjz057 
 
 
 
 
Table 2: P-values of primary outcomes using Log-rank tests and Kaplan-Meier analysis  
Primary 
Outcome 
Comparison 
 
Early – no pre-existing 
c.  
vs 
Early – pre-existing c. 
vs 
Late – no pre-existing 
c. vs 
Late – pre-existing c. 
 
(global test) 
Comparison 
 
Early vs 
Late 
 
 
no pre-existing 
complication 
Comparison 
 
Early vs 
Late 
 
 
pre-existing 
complication  
Stenosis <0.001 <0.001 0.147 
Perianal 
fistula 
0.506 0.671 0.560 
Other fistula 0.961 0.781 0.676 
Any fistula 0.627 0.413 0.519 
Perianal 
surgery 
0.002 0.935 0.846 
Intestinal 
surgery 
 
0.623 
 
0.213 
 
0.607 
Any surgery 0.927 0.702 0.892 
EIM <0.001 0.750 0.087 
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